NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
NovoCure股票交易上漲，因爲派傑投資對該股票維持了增持評級，並將目標價格從28美元提高至42美元。
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
NovoCure股票交易上漲，因爲派傑投資對該股票維持了增持評級，並將目標價格從28美元提高至42美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間